FDA OKs Merck clot drug

Share this article:

The FDA green-lighted Merck's anti-blood-clot drug vorapaxar, which will go by the brand name Zontivity.

Friday's approval is for reducing the risk of heart attack, stroke and cardiovascular death among patients who have already had a heart attack or have blocked arteries of the leg.

Reuters notes that approval was slow-going because of concerns about bleeding among clinical trial patients.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters